Article
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Journal of the National Comprehensive Cancer Network : JNCCN - 1 Oct 2023
Daly Mary B, Pal Tuya, Maxwell Kara N, Churpek Jane, Kohlmann Wendy, AlHilli Zahraa, Arun Banu, Buys Saundra S, Cheng Heather, Domchek Susan M, Friedman Susan, Giri Veda, Goggins Michael, Hagemann Andrea, Hendrix Ashley, Hutton Mollie L, Karlan Beth Y, Kassem Nawal, Khan Seema, Khoury Katia, Kurian Allison W, Laronga Christine, Mak Julie S, Mansour John, McDonnell Kevin, Menendez Carolyn S, Merajver Sofia D, Norquist Barbara S, Offit Kenneth, Rash Dominique, Reiser Gwen, Senter-Jamieson Leigha, Shannon Kristen Mahoney, Visvanathan Kala, Welborn Jeanna, Wick Myra J, Wood Marie, Yurgelun Matthew B, Dwyer Mary A, Darlow Susan D
Abstract excerpt
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these...
Topics
- Male
- Female
- Humans
- Germ-Line Mutation
- Genetic Testing
- Breast Neoplasms
- Genetic Predisposition to Disease